Form 4: Alnylam Director Dennis Ausiello Acquires Stock Options

Director Dennis Ausiello reports the acquisition of stock options in Alnylam Pharmaceuticals.

Summary

• On May 16, 2024, Dennis Ausiello, a director of Alnylam Pharmaceuticals, acquired 5,228 stock options.
• The exercise price of these options is $151.22.
• The options vest upon the earlier of the first anniversary of the grant date (May 16, 2025) or the date of retirement or resignation, provided such date occurs no more than 90 days prior to the first anniversary of the grant date.
• The expiration date for these options is May 16, 2034.
• Ausiello also has a power of attorney designating Jeffrey Poulton, Brett Budzinski, Gisele Dion, and Stephen Hall to handle Section 16 reporting obligations.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey strong positive or negative sentiment, but the acquisition could be interpreted as a sign of confidence.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in the pharmaceutical industry. Directors often receive stock options as part of their compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates